Actively Recruiting

All Genders
NCT05700565

Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype

Led by Lucie Heinzerling · Updated on 2024-03-15

50

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is an open, monocentric study. It includes patients with irAE refractory to standard therapy or patients where corticosteroids cannot be tapered. Patients will either be treated with ECP or second line immunosuppressive therapy according to investigator's choice. Patients will be followed for 24 weeks after first treatment.

CONDITIONS

Official Title

Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willing and able to comply with scheduled visits and have given written informed consent
  • Have immune-related adverse events after immune checkpoint inhibitor therapy (PD-1/PD-L1 or PD-1 + CTLA4 blockade)
  • Have immune-related adverse events refractory to corticosteroids or inability to taper corticosteroids to prednisone equivalent of 5 mg or less
  • Refractory defined as no symptom improvement within 72 hours of corticosteroids
  • Inability to taper corticosteroids defined as relapse during standard tapering of 1 mg/kg over 28 days
Not Eligible

You will not qualify if you...

  • Contraindications to extracorporeal photopheresis including sensitivity to psoralen compounds, photosensitivity conditions, aphakia, history of heparin-induced thrombocytopenia, poor cardio-circulatory function, or low hematocrit
  • Pregnancy
  • Body weight less than 40 kg

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

LMU Klinikum Hauttumorzentrum

Munich, Germany, 80337

Actively Recruiting

Loading map...

Research Team

L

Lucie Heinzerling

CONTACT

D

Dirk Tomsitz

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype | DecenTrialz